stockrowBeOne Medicines Ltd. - Sponsored ADR
BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.
- Revenue
- +33.8%
- EPS
- +143.7%
- Free cash flow
- +33.6%
- Total debt
- +491.3%
Quarter to September 2026, against a year earlier
Follow ONC
Alert me
BeOne Medicines Ltd. - Sponsored ADR (ONC) Book value per share
BeOne Medicines Ltd. - Sponsored ADR's book value per share at the end of fiscal 2025 was 40.0×, up 26.4% from 31.6× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 0.0×. Over the past ten years it has ranged from 8.7× (fiscal 2015) to 66.1× (fiscal 2021); the current reading is higher than 73% of that period. BeOne Medicines Ltd. - Sponsored ADR ranks 477th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 40.0× | 26.35% |
| FY2024 | 31.6× | (6.60%) |
| FY2023 | 33.9× | (20.27%) |
| FY2022 | 42.5× | (35.69%) |
| FY2021 | 66.1× | 42.59% |
| FY2020 | 46.4× | 184.53% |
| FY2019 | 16.3× | (48.49%) |
| FY2018 | 31.6× | 93.15% |
| FY2017 | 16.4× | 44.07% |
| FY2016 | 11.4× | 30.12% |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 46.4× | 8.09% |
| Mar 2026 | 42.9× | 7.29% |
| Dec 2025 | 40.0× | 6.73% |
| 43 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| BNTX BioNTech SE Sponsored ADR compare | 81.8× |
| INCY Incyte Corporation compare | 27.8× |
| RPRX Royalty Pharma PLC compare | 22.0× |
| RVMD Revolution Medicines, Inc. compare | 11.2× |
| GMAB Genmab A/S Sponsored ADR compare | 9.7× |
| ROIV Roivant Sciences Ltd. compare | 6.8× |
| INSM Insmed, Inc. compare | 3.3× |
| ONC BeOne Medicines Ltd. - Sponsored ADR | 0.0× |
| ARGX argenex SE compare | 0.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on ONC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement